Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,635 Breast Cancer Risk Reduction: A Patient Doctor Intervention
Breast Cancer
Primary: Knowledge of Breast Cancer Risk Factors — 48.9; 56.4 units on a scale
Phase 2 N=126 Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer
Breast Cancer
Primary: Change in Breast Epithelial Cell Proliferation as Measured by Ki-67 Labeling — .325; .289; -.418; -.461 Ki-67 labeling index
N/A N=266 Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention
Breast Cancer
Primary: Change in Absolute Breast Density — 65.53; 64.39; 65.08; 56.35 cm squared
Phase 3 N=51 Olive Oil for High Risk Breast Cancer Prevention in Women
Breast Cancer
Primary: Change in Maximum Volumetric Breast Density Percentage — -0.038 Mean decrease in max VBD percentage
N/A N=451 Project Breast47: Effect of an Educational Intervention
Breast Neoplasm · Primary Prevention · Risk Factors
Primary: Behavioral BC Risk With an Educational Intervention for Prevention — 8.10; 8.15 units on a scale
Phase 2 N=199 LY353381 in Preventing Breast Cancer in Women With Hyperplasia
Breast Cancer
Primary: Change in Masood Score — -1.1; -0.8 units on a scale
Phase 2 N=55 Study of Breast Cancer Prevention by Letrozole in High Risk Women
Breast Cancer
Primary: Change in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months — -1.5; -1.1 percentage of cells stained positive — p=0.92
Phase 2 N=1,075 Green Tea and Reduction of Breast Cancer Risk
Breast Cancer
Primary: Mammographic Density — 22.71; 21.84; 22.09; 21.13 Percent
N/A N=224 Breast Cancer: Feasibility of an Educational Intervention
Women's Health: Neoplasm of Breast
Primary: Feasibility of an Educational Intervention: Adherence to the Intervention — 99; 83 Participants
Phase 2 N=25 Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
Breast Cancer
Primary: Change in the Percentage of Breast Epithelial Cells Expressing Ki-67, From Baseline to 6 Months — -3.0 percentage of positive cells — p=<0.001
Phase 2 N=72 Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Change in Percent of Breast Epithelial Cells Staining Positive for Ki-67 — -1.2; -2.0 percentage of cells staining positive — p=0.71
N/A N=232 Predictors of Ovarian Insufficiency in Young Breast Cancer Patients
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
Phase 2 N=49 Letrozole in Preventing Breast Cancer in Postmenopausal Women
Breast Cancer
Primary: Change in Lumbar Density From Baseline to 12 Months — -0.036; -0.021 g/cm^2 — p=0.15
N/A N=40 Lung and Breast Cancer Prevention by an Integrated Intervention of Maternal Smoking Cessation and Breastfeeding
Smoking, Cigarette · Breastfeeding
Primary: Number of Participants With Smoking Abstinence — 8; 3 Participants
Phase 2 N=42 Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration. — -2.3 Change in % of cells positive for Ki-67
N/A N=615 Individual Counseling and/or Computer-Based Counseling in Helping Healthy Women Adopt a Cancer Prevention Diet
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Change in Fruit, Vegetable Consumption as Measured by Food Frequency Questionnaire at 3 Months — 2.7272727; 2.9758065; 2.7330645; 0.4720000 number of servings per day
Phase 2 N=151 Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk
Breast Cancer Prevention
Primary: Change in Breast Density at 6 Months — -5.45; -13.71 cm^3
Phase 2 N=321 Soy Protein and Breast Cancer Risk Reduction
Breast Cancer
Primary: Mammographic Density (Baseline) — 29.21; 28.24 percentage of glandular tissue in breast
Phase 1 N=24 Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
Breast Atypical Ductal Hyperplasia · Breast Atypical Lobular Hyperplasia · Breast Ductal Carcinoma In Situ
Primary: Number of Participants With Incidence of Adverse Events (Dose Limiting Toxicities) — 0; 1; 1; 0 Participants
Phase 2 N=46 Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Breast Neoplasms
Primary: Percent Change in Mammographic Density at 1 Year on Exemestane — -2.4 percent change from baseline
N/A N=24 Dietary Fat, Eicosanoids and Breast Cancer Risk
Breast Cancer
Primary: Plasma Sex Hormone Levels
Phase 2 N=197 Soy Isoflavones and Breast Cancer Risk Reduction
Breast Cancer
Primary: Fibroglandular Tissue in Total Breast (FGBT%) — 24.94; 25.34; 24.03; 25.82 percentage of total breast tissue — p=0.071
N/A N=30 Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
Breast Cancer
Primary: Change in Mammographic Breast Density Over Course of Study — -0.5 Change in percent dense breast area
Phase 3 N=300 Vitamin D and Breast Cancer Biomarkers in Female Patients
Breast Cancer
Primary: Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd Method Compared Between Arms — -3.4; -1.4 percent change
Phase 2 N=67 Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
BRCA1 Mutation Carrier · BRCA2 Mutation Carrier · Ductal Breast Carcinoma In Situ
Primary: Mean Levels of Telapristone Acetate in Breast Tissue — 2.82; 103 ng/g
N/A N=1,071 BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
Breast Cancer
Primary: Number of Eligible Women Who Received Breast Cancer Risk Assessment — 8; 56; 29 Participants
N/A N=35,953 Cancer Prevention Clinical Decision Support
Cancer Prevention
Primary: Composite Cancer Screening Tests up to Date — 3087; 2590; 3866 Participants — p=.025
Phase 2 N=158 Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast
Mammographically Dense Breast
Primary: Mammographic Breast Density Using Cumulus Software — -6.30; -5.77; -2.81; -5.43 Percent Change in Breast Density
Phase 2 N=36 Breast Cancer Risk Biomarkers in Premenopausal Women
Breast Cancer
Primary: The Proportion of Subjects That Complete an Intervention of Lovaza™ 4 Grams Per Day — 0.94 proportion of enrolled participants